Setting the record straight
By Martin H. Johnson,
Reproductive BioMedicine Online
| 12. 01. 2016
This editorial comments on a paper from Chen et al. (2016)), published in this issue of RBM Online, in an attempt to set the record straight after some shoddy scientific journalism. The paper describes the long-term outcomes of experimental treatments involving ooplasmic transfers conducted between 1996 and 2001 at Saint Barnabas Medical Centre, Livingston, New Jersey, USA (Barritt et al., 2001a). It is timely to report these findings in light of (i) a recent report of the birth of a baby after ‘mitochondrial transfer’, and (ii) because the Human Fertilisation and Embryology Authority (HFEA) in the UK is deciding whether to issue a license for treatment by mitochondrial transfer (http://www.hfea.gov.uk/10363.html).
First, the report of the birth of a baby after meiotic metaphase II spindle transfer to alleviate mitochondrial disease came not in a standard journal article, but in the form of an abstract submitted to the recent American Society for Reproductive Medicine (ASRM) meeting (Zhang et al., 2016a). In choosing this route, the authors have unfortunate form – the same authors having used the same...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Gemma Conroy, Nature | 06.27.2024
Image by Robina Weermeijer from Unsplash
A molecular-editing tool that’s small enough to be delivered to the brain shuts down the production of proteins that cause prion diseases, a rare but deadly group of neurodegenerative disorders.
The system — known...
By Mesha Maren , Salon | 07.20.2024